Regenxbio Inc (RGNX)

$8.74 +0.12 (1.39%)
Market Cap 438.40M
Revenue (ttm) 83.33M
Net Income (ttm) -227.10M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -272.53%
Debt to Equity Ratio 0.00
Volume 423,900
Avg Vol 1,128,990
Day's Range N/A - N/A
Shares Out 50.16M
Stochastic %K 79%
Beta 1.06
Analysts Strong Sell
Price Target $32.08

Company Profile

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phas...

Industry: Biotechnology
Sector: Healthcare
Phone: 240 552 8181
Address:
9804 Medical Center Drive, Rockville, United States
Biopharmlegend
Biopharmlegend Jul. 3 at 6:42 PM
$RGNX I heard this could get an adcom for pdufa in November as its novel treatment with surrogate endpoints for Hunter Syndrome?
1 · Reply
BRITLS
BRITLS Jun. 26 at 8:01 PM
$RGNX well that end of day move is interesting
0 · Reply
DCRMIA
DCRMIA Jun. 26 at 11:48 AM
$RGNX best time to get in. I'm loaded☑️📈
1 · Reply
maphere
maphere Jun. 23 at 3:13 PM
$RGNX 1 year results from fellow eye study of RGX-314 for wAMD slide deck available. chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://www.regenxbio.com/getattachment/1411ee65-162f-45af-8958-4770c77ae3a7/Abbey_Sura-vec_SR-FE_CTS-2025_FINAL_.pdf?lang=en-US&ext=.pdf
2 · Reply
MrWick007
MrWick007 Jun. 20 at 5:56 PM
$RGNX can the Linda texted text her and find out?😅
0 · Reply
maphere
maphere Jun. 19 at 6:37 PM
$RGNX 1-year results from the fellow eye study of RGX-314 for wAMD being reported this weekend at Clinical Trials at the Summit per this interview with Dr. Khanani. Previous results were released last Oct. of 9 month fellow eye results. ______________ "We are looking at data from 1-year results from the fellow eye study of RGX-314" https://www.modernretina.com/view/q-a-arshad-m-khanani-md-ma-fasrs-on-the-cts-2025-meeting Oct 2024 PR https://ir.regenxbio.com/news-releases/news-release-details/regenxbio-presents-positive-data-phase-ii-study-subretinal-abbv
1 · Reply
Redposition
Redposition Jun. 19 at 3:58 PM
$RGNX AFFINITY DUCHENNE’s primary endpoint is safety, with a biomarker endpoint of microdystrophin expression. Regenxbio reported no serious adverse effects. Notably, patients taking RGX-202 are given immunosuppressants to tamp down on those effects, something not done with Elevidys, according to the BMO analysts.
0 · Reply
DarkOrb
DarkOrb Jun. 18 at 7:27 PM
$RGNX Following up on the 2nd SRPT fatality news on Sunday, Adam Feuerstein reported on Monday that there is a third boy that has been repeatedly hospitalized with potential liver failure since being dosed in April. I haven't seen much discussion of this, but there is possibly more bad news in the future on this, although obviously I'm hoping for a good resolution for the third boy. Here's the X link, there is also an associated article, but it is paywalled. https://x.com/adamfeuerstein/status/1934692686126100901
0 · Reply
BRITLS
BRITLS Jun. 18 at 4:22 AM
$RGNX what's the next potential news? Trying to gauge when this will level off
1 · Reply
LongRKvis
LongRKvis Jun. 17 at 7:43 PM
$RGNX 3 Pivotal phase III Next 12 months.
0 · Reply
Latest News on RGNX
Regenxbio's RGX-121 Could Become The New Standard Of Care In Hunter Syndrome

Jun 6, 2025, 4:02 PM EDT - 4 weeks ago

Regenxbio's RGX-121 Could Become The New Standard Of Care In Hunter Syndrome

Early Wins: RegenXBio's Gene Therapy Helps Duchenne Patients Walk Stronger, Longer

Jun 5, 2025, 11:43 AM EDT - 4 weeks ago

Early Wins: RegenXBio's Gene Therapy Helps Duchenne Patients Walk Stronger, Longer

REGENXBIO REPORTS NEW POSITIVE FUNCTIONAL DATA FROM PHASE I/II AFFINITY DUCHENNE® TRIAL OF RGX-202

Jun 5, 2025, 7:05 AM EDT - 4 weeks ago

REGENXBIO REPORTS NEW POSITIVE FUNCTIONAL DATA FROM PHASE I/II AFFINITY DUCHENNE® TRIAL OF RGX-202

REGENXBIO to Host Webcast Discussing Interim Functional Data from the Phase I/II AFFINITY DUCHENNE® Trial of RGX-202

Jun 2, 2025, 7:05 AM EDT - 4 weeks ago

REGENXBIO to Host Webcast Discussing Interim Functional Data from the Phase I/II AFFINITY DUCHENNE® Trial of RGX-202

REGENXBIO Announces Strategic Royalty Monetization Agreement for Up to $250 Million

May 19, 2025, 4:05 PM EDT - 6 weeks ago

REGENXBIO Announces Strategic Royalty Monetization Agreement for Up to $250 Million

FDA Accepts Biologics License Application for Mucopolysaccharidosis II Treatment

May 14, 2025, 7:13 AM EDT - 7 weeks ago

FDA Accepts Biologics License Application for Mucopolysaccharidosis II Treatment

REGENXBIO Inc. (RGNX) Q1 2025 Earnings Call Transcript

May 13, 2025, 7:07 AM EDT - 7 weeks ago

REGENXBIO Inc. (RGNX) Q1 2025 Earnings Call Transcript

REGENXBIO Announces FDA Acceptance and Priority Review of the BLA for RGX-121 for MPS II

May 13, 2025, 7:05 AM EDT - 7 weeks ago

REGENXBIO Announces FDA Acceptance and Priority Review of the BLA for RGX-121 for MPS II

REGENXBIO Reports First Quarter 2025 Financial Results and Recent Operational Highlights

May 12, 2025, 4:05 PM EDT - 7 weeks ago

REGENXBIO Reports First Quarter 2025 Financial Results and Recent Operational Highlights

REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 28th Annual Meeting

May 8, 2025, 7:05 AM EDT - 2 months ago

REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 28th Annual Meeting

REGENXBIO to Participate in Upcoming Investor Conferences

May 6, 2025, 7:05 AM EDT - 2 months ago

REGENXBIO to Participate in Upcoming Investor Conferences

REGENXBIO to Host Conference Call on May 12 to Discuss First Quarter 2025 Financial Results and Recent Operational Highlights

Apr 30, 2025, 4:05 PM EDT - 2 months ago

REGENXBIO to Host Conference Call on May 12 to Discuss First Quarter 2025 Financial Results and Recent Operational Highlights

5 Reasons To Buy Regenxbio Right Now

Mar 26, 2025, 12:31 PM EDT - 3 months ago

5 Reasons To Buy Regenxbio Right Now

REGENXBIO REPORTS POSITIVE BIOMARKER DATA FROM AFFINITY DUCHENNE® TRIAL OF RGX-202 GENE THERAPY

Mar 19, 2025, 9:15 AM EDT - 3 months ago

REGENXBIO REPORTS POSITIVE BIOMARKER DATA FROM AFFINITY DUCHENNE® TRIAL OF RGX-202 GENE THERAPY

REGENXBIO Inc. (RGNX) Q4 2024 Earnings Call Transcript

Mar 13, 2025, 6:44 PM EDT - 4 months ago

REGENXBIO Inc. (RGNX) Q4 2024 Earnings Call Transcript

REGENXBIO Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Updates

Mar 13, 2025, 4:05 PM EDT - 4 months ago

REGENXBIO Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Updates

REGENXBIO Announces Presentations at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Mar 10, 2025, 7:05 AM EDT - 4 months ago

REGENXBIO Announces Presentations at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

REGENXBIO Announces Closing of Strategic Partnership with Nippon Shinyaku for MPS Diseases

Mar 4, 2025, 7:31 AM EST - 4 months ago

REGENXBIO Announces Closing of Strategic Partnership with Nippon Shinyaku for MPS Diseases

REGENXBIO to Host Conference Call on March 13 to Discuss Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Highlights

Feb 26, 2025, 4:05 PM EST - 4 months ago

REGENXBIO to Host Conference Call on March 13 to Discuss Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Highlights

Regenxbio's Gene Therapy Outlook Dims As Rival Treatments Gain Ground, Goldman Sachs Warns

Feb 11, 2025, 3:20 PM EST - 5 months ago

Regenxbio's Gene Therapy Outlook Dims As Rival Treatments Gain Ground, Goldman Sachs Warns

REGENXBIO Announces Presentations of RGX-121 at the 21st Annual WORLDSymposium 2025

Jan 30, 2025, 7:05 AM EST - 5 months ago

REGENXBIO Announces Presentations of RGX-121 at the 21st Annual WORLDSymposium 2025

Regenxbio: Wet AMD ABBV-RGX-314 Results Remain On Track For 2026

Jan 16, 2025, 4:01 AM EST - 6 months ago

Regenxbio: Wet AMD ABBV-RGX-314 Results Remain On Track For 2026

AMD

Regenxbio Inc.: Why It Is Down, And When It Will Go Up Again

Jan 15, 2025, 3:27 PM EST - 6 months ago

Regenxbio Inc.: Why It Is Down, And When It Will Go Up Again

REGENXBIO and Nippon Shinyaku Announce Exclusive Partnership to Develop and Commercialize RGX-121 and RGX-111 for MPS Diseases

Jan 14, 2025, 5:00 AM EST - 6 months ago

REGENXBIO and Nippon Shinyaku Announce Exclusive Partnership to Develop and Commercialize RGX-121 and RGX-111 for MPS Diseases

AbbVie and REGENXBIO Announce Updates on the ABBV-RGX-314 Clinical Program

Jan 13, 2025, 8:31 AM EST - 6 months ago

AbbVie and REGENXBIO Announce Updates on the ABBV-RGX-314 Clinical Program

ABBV

Apollo Global Management and Workday Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

Dec 6, 2024, 6:29 PM EST - 7 months ago

Apollo Global Management and Workday Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

AMTM APO CMA CRI CRS HPP KELYA

REGENXBIO INITIATES PIVOTAL PHASE OF AFFINITY DUCHENNE® TRIAL OF RGX-202 GENE THERAPY AND REPORTS POSITIVE FUNCTIONAL DATA

Nov 18, 2024, 7:05 AM EST - 8 months ago

REGENXBIO INITIATES PIVOTAL PHASE OF AFFINITY DUCHENNE® TRIAL OF RGX-202 GENE THERAPY AND REPORTS POSITIVE FUNCTIONAL DATA

REGENXBIO to Host Webcast Discussing Pivotal Program and First Functional Data from the AFFINITY DUCHENNE® Trial of RGX-202

Nov 14, 2024, 7:05 AM EST - 8 months ago

REGENXBIO to Host Webcast Discussing Pivotal Program and First Functional Data from the AFFINITY DUCHENNE® Trial of RGX-202

REGENXBIO Inc. (RGNX) Q3 2024 Earnings Call Transcript

Nov 6, 2024, 11:16 PM EST - 8 months ago

REGENXBIO Inc. (RGNX) Q3 2024 Earnings Call Transcript

REGENXBIO Reports Third Quarter 2024 Financial Results and Recent Operational Updates

Nov 6, 2024, 4:05 PM EST - 8 months ago

REGENXBIO Reports Third Quarter 2024 Financial Results and Recent Operational Updates

REGENXBIO: With Additional MPS II Data, Program Advancement Remains On Track

Oct 31, 2024, 3:38 PM EDT - 8 months ago

REGENXBIO: With Additional MPS II Data, Program Advancement Remains On Track

REGENXBIO to Host Conference Call on November 6 to Discuss Third Quarter 2024 Financial Results and Recent Operational Highlights

Oct 30, 2024, 7:05 AM EDT - 8 months ago

REGENXBIO to Host Conference Call on November 6 to Discuss Third Quarter 2024 Financial Results and Recent Operational Highlights

REGENXBIO Presents Positive Data from the Phase II Study of Subretinal ABBV-RGX-314 in Patients with Bilateral Wet AMD at AAO 2024

Oct 21, 2024, 7:05 AM EDT - 9 months ago

REGENXBIO Presents Positive Data from the Phase II Study of Subretinal ABBV-RGX-314 in Patients with Bilateral Wet AMD at AAO 2024

REGENXBIO Announces Presentations at the American Academy of Ophthalmology 2024 Annual Meeting

Oct 18, 2024, 7:05 AM EDT - 9 months ago

REGENXBIO Announces Presentations at the American Academy of Ophthalmology 2024 Annual Meeting

REGENXBIO to Participate in Chardan's 8th Annual Genetic Medicines Conference

Sep 23, 2024, 4:05 PM EDT - 10 months ago

REGENXBIO to Participate in Chardan's 8th Annual Genetic Medicines Conference

REGENXBIO Appoints Mitchell Chan as Chief Financial Officer

Sep 17, 2024, 7:05 AM EDT - 10 months ago

REGENXBIO Appoints Mitchell Chan as Chief Financial Officer

REGENXBIO Announces Positive Data from Pivotal Dose Level of RGX-121 Demonstrating Long-Term Systemic Effect

Sep 3, 2024, 8:04 AM EDT - 10 months ago

REGENXBIO Announces Positive Data from Pivotal Dose Level of RGX-121 Demonstrating Long-Term Systemic Effect

REGENXBIO Announces Presentation at the Society for the Study of Inborn Errors of Metabolism (SSIEM) 2024 Annual Symposium

Aug 27, 2024, 7:05 AM EDT - 11 months ago

REGENXBIO Announces Presentation at the Society for the Study of Inborn Errors of Metabolism (SSIEM) 2024 Annual Symposium

REGENXBIO to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

Aug 8, 2024, 7:05 AM EDT - 11 months ago

REGENXBIO to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

Regenxbio: RGX-121 Could Achieve A First For Rare Neurodegenerative Disorder

Aug 6, 2024, 4:03 PM EDT - 11 months ago

Regenxbio: RGX-121 Could Achieve A First For Rare Neurodegenerative Disorder

REGENXBIO Inc. (RGNX) Q2 2024 Earnings Call Transcript

Aug 1, 2024, 11:06 PM EDT - 1 year ago

REGENXBIO Inc. (RGNX) Q2 2024 Earnings Call Transcript

REGENXBIO Reports Second Quarter 2024 Financial Results and Recent Operational Highlights

Aug 1, 2024, 4:05 PM EDT - 1 year ago

REGENXBIO Reports Second Quarter 2024 Financial Results and Recent Operational Highlights

REGENXBIO ANNOUNCES NEW POSITIVE DATA FROM AFFINITY DUCHENNE® TRIAL OF RGX-202

Aug 1, 2024, 7:03 AM EDT - 1 year ago

REGENXBIO ANNOUNCES NEW POSITIVE DATA FROM AFFINITY DUCHENNE® TRIAL OF RGX-202

REGENXBIO to Host Conference Call on August 1 to Discuss Second Quarter 2024 Financial Results and Recent Operational Highlights

Jul 25, 2024, 7:05 AM EDT - 1 year ago

REGENXBIO to Host Conference Call on August 1 to Discuss Second Quarter 2024 Financial Results and Recent Operational Highlights

REGENXBIO Announces Expansion of AFFINITY DUCHENNE® Trial to Include a New Cohort of Younger Patients

Jun 24, 2024, 7:05 AM EDT - 1 year ago

REGENXBIO Announces Expansion of AFFINITY DUCHENNE® Trial to Include a New Cohort of Younger Patients

REGENXBIO Announces Successful Pre-BLA Meeting with FDA to Support Accelerated Approval Pathway for RGX-121 for the Treatment of MPS II

Jun 18, 2024, 7:05 AM EDT - 1 year ago

REGENXBIO Announces Successful Pre-BLA Meeting with FDA to Support Accelerated Approval Pathway for RGX-121 for the Treatment of MPS II

REGENXBIO Announces Leadership Transition

Jun 12, 2024, 7:05 AM EDT - 1 year ago

REGENXBIO Announces Leadership Transition

Regenxbio: Transforming Gene Therapy With Innovative AAV Treatments, Strong Buy

Jun 10, 2024, 11:55 PM EDT - 1 year ago

Regenxbio: Transforming Gene Therapy With Innovative AAV Treatments, Strong Buy

REGENXBIO to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Jun 5, 2024, 7:05 AM EDT - 1 year ago

REGENXBIO to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

REGENXBIO Inc. (RGNX) Q1 2024 Earnings Call Transcript

May 8, 2024, 9:42 PM EDT - 1 year ago

REGENXBIO Inc. (RGNX) Q1 2024 Earnings Call Transcript

Biopharmlegend
Biopharmlegend Jul. 3 at 6:42 PM
$RGNX I heard this could get an adcom for pdufa in November as its novel treatment with surrogate endpoints for Hunter Syndrome?
1 · Reply
BRITLS
BRITLS Jun. 26 at 8:01 PM
$RGNX well that end of day move is interesting
0 · Reply
DCRMIA
DCRMIA Jun. 26 at 11:48 AM
$RGNX best time to get in. I'm loaded☑️📈
1 · Reply
maphere
maphere Jun. 23 at 3:13 PM
$RGNX 1 year results from fellow eye study of RGX-314 for wAMD slide deck available. chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://www.regenxbio.com/getattachment/1411ee65-162f-45af-8958-4770c77ae3a7/Abbey_Sura-vec_SR-FE_CTS-2025_FINAL_.pdf?lang=en-US&ext=.pdf
2 · Reply
MrWick007
MrWick007 Jun. 20 at 5:56 PM
$RGNX can the Linda texted text her and find out?😅
0 · Reply
maphere
maphere Jun. 19 at 6:37 PM
$RGNX 1-year results from the fellow eye study of RGX-314 for wAMD being reported this weekend at Clinical Trials at the Summit per this interview with Dr. Khanani. Previous results were released last Oct. of 9 month fellow eye results. ______________ "We are looking at data from 1-year results from the fellow eye study of RGX-314" https://www.modernretina.com/view/q-a-arshad-m-khanani-md-ma-fasrs-on-the-cts-2025-meeting Oct 2024 PR https://ir.regenxbio.com/news-releases/news-release-details/regenxbio-presents-positive-data-phase-ii-study-subretinal-abbv
1 · Reply
Redposition
Redposition Jun. 19 at 3:58 PM
$RGNX AFFINITY DUCHENNE’s primary endpoint is safety, with a biomarker endpoint of microdystrophin expression. Regenxbio reported no serious adverse effects. Notably, patients taking RGX-202 are given immunosuppressants to tamp down on those effects, something not done with Elevidys, according to the BMO analysts.
0 · Reply
DarkOrb
DarkOrb Jun. 18 at 7:27 PM
$RGNX Following up on the 2nd SRPT fatality news on Sunday, Adam Feuerstein reported on Monday that there is a third boy that has been repeatedly hospitalized with potential liver failure since being dosed in April. I haven't seen much discussion of this, but there is possibly more bad news in the future on this, although obviously I'm hoping for a good resolution for the third boy. Here's the X link, there is also an associated article, but it is paywalled. https://x.com/adamfeuerstein/status/1934692686126100901
0 · Reply
BRITLS
BRITLS Jun. 18 at 4:22 AM
$RGNX what's the next potential news? Trying to gauge when this will level off
1 · Reply
LongRKvis
LongRKvis Jun. 17 at 7:43 PM
$RGNX 3 Pivotal phase III Next 12 months.
0 · Reply
WaveRB77
WaveRB77 Jun. 17 at 2:46 AM
$RGNX RGNX has 3 world class drugs.Dont forget MPS 121 OR RGNX314. BOTH drugs Offer huge potential.
1 · Reply
DarkOrb
DarkOrb Jun. 16 at 4:51 PM
$RGNX Not too bad considering what has happened to SRPT today.
1 · Reply
Florestan
Florestan Jun. 16 at 2:08 PM
$RGNX as I was saying.
1 · Reply
BRITLS
BRITLS Jun. 16 at 2:07 PM
$RGNX sigh..
0 · Reply
waterlock
waterlock Jun. 16 at 1:18 PM
$RGNX I remembered some haters keep saying 202 needs premedication and so on. I have always argued that for such a serious illness, premedication is absolutely nothing. It takes two lives for SRPT to do what they should and can do at a much earlier stage. https://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-provides-safety-update-elevidys-and-initiates-steps
1 · Reply
tomorrowverse
tomorrowverse Jun. 16 at 3:31 AM
$RGNX 2 patient death on SRPT ELEVIDYS should not negatively correlate to RGX-202. Rather, it strengthens RGX-202's superior safety profile for several reasons. 1) RGX-202 uses vector AAV8 vs SRPT's rh74 and PFE's AAV9. 2) Novartis has been globally selling > $1 billion blockbuster drug ZOLGENSMA for SMA developed using RGNX's AAV8 vector. 3) RGX-202 has C-terminal domain and depleted CpG deletion, which benefit expression and immunogenicity. 4) RGNX's superior cGMP manufacturing consistency/purity > 80% allows less total vector load. #3 & #4 are from BoA's research report. I believe RGX-202 will become the best-in-class DMD gene therapy!
3 · Reply
DarkOrb
DarkOrb Jun. 15 at 4:18 PM
$RGNX For those of you who haven't seen, there was another SRPT ELEVIDYS patient death announced today (Sunday) due to liver failure in a non-ambulatory DMD patient and they are suspending shipment for all non-ambulatory patients. Probably going to be bad for RGNX on Monday. https://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-provides-safety-update-elevidys-and-initiates-steps
2 · Reply
BRITLS
BRITLS Jun. 13 at 8:19 PM
$RGNX I'm seeing 5 peaks in 3 months. Volatility is wild ha
0 · Reply
bullwink
bullwink Jun. 13 at 3:53 PM
$RGNX xbi down .54%, we are down 6.3% Unbelievable
2 · Reply
BRITLS
BRITLS Jun. 13 at 2:50 PM
$RGNX pretty big sell candle at the low
0 · Reply
maphere
maphere Jun. 12 at 2:26 PM
$RGNX Regenxbio being hosted for a private financial firm's event next Wed. https://forcefamilyoffice.com/events/healthcare/regenexbio-coming-june-18-2025/
1 · Reply
BRITLS
BRITLS Jun. 11 at 5:49 PM
$RGNX seemed to recover very quickly after the read out. Very strange. Anything else brewing?
1 · Reply